Dr Antonio González-Martín speaks to ecancer at ESMO 2019 in Barcelona about the PRIMA/ENGOT-OV26/GOG-3012 study.

He outlines the randomised, double-blind, phase 3 trial. Patients with newly diagnosed advanced ovarian cancer were randomly assigned to receive niraparib or placebo after a response to platinum-based chemotherapy.

Among patients with newly diagnosed advanced ovarian cancer who had a response to platinum-based chemotherapy, those who received niraparib had significantly longer progression-free survival than those who received placebo, regardless of the presence or absence of homologous-recombination deficiency.